Cargando…

Cardiac Acetylation in Metabolic Diseases

Lysine acetylation is a highly conserved mechanism that affects several biological processes such as cell growth, metabolism, enzymatic activity, subcellular localization of proteins, gene transcription or chromatin structure. This post-translational modification, mainly regulated by lysine acetyltr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubois-Deruy, Emilie, El Masri, Yara, Turkieh, Annie, Amouyel, Philippe, Pinet, Florence, Annicotte, Jean-Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405459/
https://www.ncbi.nlm.nih.gov/pubmed/36009379
http://dx.doi.org/10.3390/biomedicines10081834
_version_ 1784773885999185920
author Dubois-Deruy, Emilie
El Masri, Yara
Turkieh, Annie
Amouyel, Philippe
Pinet, Florence
Annicotte, Jean-Sébastien
author_facet Dubois-Deruy, Emilie
El Masri, Yara
Turkieh, Annie
Amouyel, Philippe
Pinet, Florence
Annicotte, Jean-Sébastien
author_sort Dubois-Deruy, Emilie
collection PubMed
description Lysine acetylation is a highly conserved mechanism that affects several biological processes such as cell growth, metabolism, enzymatic activity, subcellular localization of proteins, gene transcription or chromatin structure. This post-translational modification, mainly regulated by lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) enzymes, can occur on histone or non-histone proteins. Several studies have demonstrated that dysregulated acetylation is involved in cardiac dysfunction, associated with metabolic disorder or heart failure. Since the prevalence of obesity, type 2 diabetes or heart failure rises and represents a major cause of cardiovascular morbidity and mortality worldwide, cardiac acetylation may constitute a crucial pathway that could contribute to disease development. In this review, we summarize the mechanisms involved in the regulation of cardiac acetylation and its roles in physiological conditions. In addition, we highlight the effects of cardiac acetylation in physiopathology, with a focus on obesity, type 2 diabetes and heart failure. This review sheds light on the major role of acetylation in cardiovascular diseases and emphasizes KATs and KDACs as potential therapeutic targets for heart failure.
format Online
Article
Text
id pubmed-9405459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94054592022-08-26 Cardiac Acetylation in Metabolic Diseases Dubois-Deruy, Emilie El Masri, Yara Turkieh, Annie Amouyel, Philippe Pinet, Florence Annicotte, Jean-Sébastien Biomedicines Review Lysine acetylation is a highly conserved mechanism that affects several biological processes such as cell growth, metabolism, enzymatic activity, subcellular localization of proteins, gene transcription or chromatin structure. This post-translational modification, mainly regulated by lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) enzymes, can occur on histone or non-histone proteins. Several studies have demonstrated that dysregulated acetylation is involved in cardiac dysfunction, associated with metabolic disorder or heart failure. Since the prevalence of obesity, type 2 diabetes or heart failure rises and represents a major cause of cardiovascular morbidity and mortality worldwide, cardiac acetylation may constitute a crucial pathway that could contribute to disease development. In this review, we summarize the mechanisms involved in the regulation of cardiac acetylation and its roles in physiological conditions. In addition, we highlight the effects of cardiac acetylation in physiopathology, with a focus on obesity, type 2 diabetes and heart failure. This review sheds light on the major role of acetylation in cardiovascular diseases and emphasizes KATs and KDACs as potential therapeutic targets for heart failure. MDPI 2022-07-29 /pmc/articles/PMC9405459/ /pubmed/36009379 http://dx.doi.org/10.3390/biomedicines10081834 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dubois-Deruy, Emilie
El Masri, Yara
Turkieh, Annie
Amouyel, Philippe
Pinet, Florence
Annicotte, Jean-Sébastien
Cardiac Acetylation in Metabolic Diseases
title Cardiac Acetylation in Metabolic Diseases
title_full Cardiac Acetylation in Metabolic Diseases
title_fullStr Cardiac Acetylation in Metabolic Diseases
title_full_unstemmed Cardiac Acetylation in Metabolic Diseases
title_short Cardiac Acetylation in Metabolic Diseases
title_sort cardiac acetylation in metabolic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405459/
https://www.ncbi.nlm.nih.gov/pubmed/36009379
http://dx.doi.org/10.3390/biomedicines10081834
work_keys_str_mv AT duboisderuyemilie cardiacacetylationinmetabolicdiseases
AT elmasriyara cardiacacetylationinmetabolicdiseases
AT turkiehannie cardiacacetylationinmetabolicdiseases
AT amouyelphilippe cardiacacetylationinmetabolicdiseases
AT pinetflorence cardiacacetylationinmetabolicdiseases
AT annicottejeansebastien cardiacacetylationinmetabolicdiseases